B Leeneman

430 total citations
16 papers, 158 citations indexed

About

B Leeneman is a scholar working on Oncology, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, B Leeneman has authored 16 papers receiving a total of 158 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Economics and Econometrics and 4 papers in Molecular Biology. Recurrent topics in B Leeneman's work include Cutaneous Melanoma Detection and Management (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and CAR-T cell therapy research (3 papers). B Leeneman is often cited by papers focused on Cutaneous Melanoma Detection and Management (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and CAR-T cell therapy research (3 papers). B Leeneman collaborates with scholars based in Netherlands, Germany and United States. B Leeneman's co-authors include M Franken, Carin A. Uyl‐de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Hedwig M. Blommestein, Alexander C. J. van Akkooi, Pieter van Baal, Hans M. Westgeest, Jacobus J. M. van der Hoeven and Naomi van der Linden and has published in prestigious journals such as European Journal of Cancer, Cancers and Medical Decision Making.

In The Last Decade

B Leeneman

14 papers receiving 155 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B Leeneman Netherlands 6 110 40 21 20 19 16 158
Ana Maria Fagundes Sortino Brazil 5 148 1.3× 33 0.8× 10 0.5× 34 1.7× 5 0.3× 10 196
Diego Enrico Argentina 8 136 1.2× 42 1.1× 17 0.8× 7 0.3× 45 2.4× 29 215
Jorge Dunstan Peru 7 132 1.2× 31 0.8× 4 0.2× 12 0.6× 44 2.3× 17 163
Michal Kiciński Belgium 8 200 1.8× 80 2.0× 10 0.5× 6 0.3× 71 3.7× 25 268
J. Salvador Spain 7 79 0.7× 12 0.3× 17 0.8× 5 0.3× 18 0.9× 25 115
Laurien J. Zeverijn Netherlands 7 95 0.9× 81 2.0× 5 0.2× 6 0.3× 17 0.9× 24 205
Patricia Glynn United States 6 75 0.7× 32 0.8× 6 0.3× 5 0.3× 18 0.9× 10 148
Philip Tsau Choong Iau Singapore 8 51 0.5× 92 2.3× 6 0.3× 19 0.9× 26 1.4× 22 247
Elena Mata Spain 8 143 1.3× 16 0.4× 7 0.3× 5 0.3× 23 1.2× 14 196
Carlos Aguado Spain 9 174 1.6× 47 1.2× 5 0.2× 8 0.4× 13 0.7× 41 241

Countries citing papers authored by B Leeneman

Since Specialization
Citations

This map shows the geographic impact of B Leeneman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B Leeneman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B Leeneman more than expected).

Fields of papers citing papers by B Leeneman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B Leeneman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B Leeneman. The network helps show where B Leeneman may publish in the future.

Co-authorship network of co-authors of B Leeneman

This figure shows the co-authorship network connecting the top 25 collaborators of B Leeneman. A scholar is included among the top collaborators of B Leeneman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B Leeneman. B Leeneman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Groot, Saskia de, Hedwig M. Blommestein, B Leeneman, et al.. (2025). Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma. Medical Decision Making. 45(3). 302–317.
2.
Leeneman, B, W. Edward Fiets, Wouter K. de Jong, et al.. (2024). Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness. European Journal of Cancer. 202. 114002–114002. 1 indexed citations
3.
Blommestein, Hedwig M., Saskia de Groot, B Leeneman, et al.. (2024). Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model. European Journal of Cancer. 218. 115071–115071.
4.
Leeneman, B, Anne‐Marie C. Dingemans, W. Edward Fiets, et al.. (2024). Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not?. European Journal of Cancer. 209. 114262–114262. 1 indexed citations
5.
Leeneman, B, Hedwig M. Blommestein, Willem E. Fibbe, et al.. (2023). Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease. European Journal Of Haematology. 111(2). 240–246. 1 indexed citations
6.
Leeneman, B, K. Schreuder, Carin A. Uyl‐de Groot, et al.. (2021). Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study. European Journal of Cancer. 154. 111–119. 27 indexed citations
7.
Franken, M, B Leeneman, Maureen J.B. Aarts, et al.. (2021). Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open. 6(6). 100320–100320. 21 indexed citations
8.
Leeneman, B, Hedwig M. Blommestein, Veerle M.H. Coupé, et al.. (2021). Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. Melanoma Research. 31(3). 249–257. 3 indexed citations
9.
Leeneman, B, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, et al.. (2020). Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers. 12(4). 1003–1003. 12 indexed citations
10.
Franken, M, et al.. (2019). A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer. 123. 58–71. 31 indexed citations
11.
Leeneman, B, M Franken, Veerle M.H. Coupé, et al.. (2019). Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. European Journal of Surgical Oncology. 45(5). 825–831. 21 indexed citations
12.
Leeneman, B, et al.. (2018). PRM19 - REPORTING FOLLOW-UP IN SURVIVAL ANALYSES: INFORMATIVE OR NOT?. Value in Health. 21. S358–S359. 2 indexed citations
13.
Franken, M, B Leeneman, Nasuh Büyükkaramikli, et al.. (2017). Comparative Effectiveness Of Novel Treatments For Advanced Melanoma: A Systematic Literature Review And Network Meta-Analysis Of Effectiveness And Safety Outcomes. Value in Health. 20(9). A412–A413. 1 indexed citations
14.
15.
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Maria Fagundes Sortino Breakdown of academic impact, for papers by Diego Enrico Breakdown of academic impact, for papers by Jorge Dunstan Breakdown of academic impact, for papers by Michal Kiciński Breakdown of academic impact, for papers by J. Salvador Breakdown of academic impact, for papers by Laurien J. Zeverijn Breakdown of academic impact, for papers by Patricia Glynn Breakdown of academic impact, for papers by Philip Tsau Choong Iau Breakdown of academic impact, for papers by Elena Mata Breakdown of academic impact, for papers by Carlos Aguado
Rankless by CCL
2026